Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 8/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 6/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122898 | 0.87 | METTL3 (0.43) | KDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL4165845 | 0.86 | KDM4E (0.41) | KDM4EHPGDHSD17B10ALDH1A1DAGLA | |
| SCHEMBL3676086 | 0.84 | KDM4E (0.56) | KDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL2123467 | 0.81 | HCRTR1 (0.54) | HTR2B | |
| SCHEMBL8151706 | 0.81 | KDM4E (0.36) | KDM4EHPGDHSD17B10ALDH1A1DAGLA | |
| SCHEMBL2616557 | 0.79 | HCRTR1 (0.57) | — | |
| SCHEMBL27808115 | 0.78 | KDM4E (0.54) | KDM4EHPGDHSD17B10ALDH1A1DAGLA | |
| SCHEMBL4163082 | 0.78 | KDM4E (0.54) | KDM4EHPGDHSD17B10ALDH1A1DAGLA | |
| SCHEMBL8142375 | 0.78 | KDM4E (0.35) | KDM4EHPGDHSD17B10ALDH1A1DAGLA | |
| SCHEMBL4153904 | 0.77 | MCHR1 (0.42) | KDM4EHPGDALDH1A1DAGLAABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | KDM4E 3080/4885HPGD 1940/4885HSD17B10 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.